pentapeptide
Is Ipamorelin legal?
Answer
Ipamorelin is not authorised or registered in any of the 10 registers read.
Each row is what that country's own register said on the date shown. Not legal advice.
| Country | Status | Products on the register | Register | Read |
|---|---|---|---|---|
| United States | Not on the register | - | Regulator FDA | 2026-10-03 |
| European Union | Not on the register | - | Regulator EMA | 2026-08-31 |
| United Kingdom | Not on the register | - | Regulator MHRA | 2026-09-03 |
| Canada | Not on the register | - | Regulator Health Canada | 2026-09-03 |
| Australia | Status unknown | - | TGA | Not read yet |
| Switzerland | Not on the register | - | Regulator Swissmedic | 2026-09-03 |
| Brazil | Not on the register | - | Regulator ANVISA | 2026-09-03 |
| Serbia | Not on the register | - | Regulator ALIMS | 2026-09-03 |
| Singapore | Not on the register | - | Regulator HSA | 2026-09-03 |
| Turkey | Not on the register | - | Regulator TITCK | 2026-09-03 |
A country not listed has no register read yet; see the world map. EU decisions also apply in Iceland, Liechtenstein and Norway.
FDA COMPOUNDING LIST (503A)
Ipamorelin is on FDA's 503A bulk-substances list (nominated for compounding, withdrawn by the nominator).
Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. The agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.
Regulator FDA list, read 2026-10-03. Not legal advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.